Of note, on their own ineffective low doses of Met/Phen and 2DG/DCA effectively suppressed clonogenic growth when combined, without losing specificity for mTOR-activated (H460res) cells, suggesting that mechanistically distinct metabolic drugs can be combined at more tolerable low doses to effectively eradicate mTOR-activated tumor cells while sparing normal cells (Supplementary Fig. 4c). The gene discussed is MTOR; the disease is neoplasm.